Tema Oncology ETF (CANC) Holdings
CANC holdings summary
as of Oct 24, 2026- Holdings
- 58 positions listed
- Top 10 weight
- 42.6% of net assets
- Effective holdings
- 34 equal-weight equivalent
- Largest holding
- RVMD 5.62% Revolution Medicines, Inc.
- Annual turnover
- 0.0% of the portfolio traded
All CANC holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines, Inc. | Healthcare | 5.62% | $11.9M | $38.14B | — |
| 2 | MRK | Merck & Co., Inc. | Healthcare | 5.30% | $11.2M | $360.08B | 115.8 |
| 3 | LLY | Eli Lilly and Company | Healthcare | 4.96% | $10.5M | $1.12T | 42.2 |
| 4 | COGT | Cogent Biosciences, Inc. | Healthcare | 4.81% | $10.1M | $5.12B | — |
| 5 | NOVN | Novartis AG | Healthcare | 3.85% | $8.1M | — | — |
| 6 | ABBV | AbbVie Inc. | Healthcare | 3.76% | $7.9M | $504.37B | 80.6 |
| 7 | GMAB | Genmab A/S | Healthcare | 3.70% | $7.8M | $22.75B | 29.1 |
| 8 | HALO | Halozyme Therapeutics, Inc. | Healthcare | 3.63% | $7.7M | $13.83B | 35.6 |
| 9 | ONC | BeiGene, Ltd. | Healthcare | 3.59% | $7.6M | $41.99B | 66.0 |
| 10 | EXEL | Exelixis, Inc. | Healthcare | 3.37% | $7.1M | $15.42B | 19.6 |
| 11 | IOVA | Iovance Biotherapeutics, Inc. | Healthcare | 3.20% | $6.8M | $6.17B | — |
| 12 | RHHBY | Roche Holding Ltd ADR | Healthcare | 3.18% | $6.7M | — | — |
| 13 | BBIO | BridgeBio Pharma, Inc. | Healthcare | 2.74% | $5.8M | $12.98B | — |
| 14 | BMY | Bristol-Myers Squibb Company | Healthcare | 2.68% | $5.7M | $122.05B | 13.2 |
| 15 | IDYA | IDEAYA Biosciences, Inc. | Healthcare | 2.53% | $5.3M | $3.17B | — |
| 16 | JNJ | Johnson & Johnson | Healthcare | 2.43% | $5.1M | $615.87B | 38.8 |
| 17 | ELVN | Enliven Therapeutics, Inc. | Healthcare | 2.41% | $5.1M | $2.73B | — |
| 18 | CGON | CG Oncology, Inc. | Healthcare | 2.39% | $5.0M | $5.31B | — |
| 19 | IMNM | Immunome, Inc. | Healthcare | 2.29% | $4.8M | $1.94B | — |
| 20 | AZN | AstraZeneca PLC | Healthcare | 2.13% | $4.5M | — | — |
| 21 | RLAY | Relay Therapeutics, Inc. | Healthcare | 1.97% | $4.1M | $3.57B | — |
| 22 | ERAS | Erasca, Inc. | Healthcare | 1.92% | $4.1M | $4.68B | — |
| 23 | ZLAB | Zai Lab Limited | Healthcare | 1.88% | $4.0M | $2.60B | — |
| 24 | LEGN | Legend Biotech Corporation | Healthcare | 1.80% | $3.8M | $3.59B | — |
| 25 | SMMT | Summit Therapeutics Inc. | Healthcare | 1.59% | $3.4M | $11.67B | — |
| 26 | AMGN | Amgen Inc. | Healthcare | 1.44% | $3.0M | $233.82B | 26.9 |
| 27 | ZA8 | ZYMEWORKS DL-00001 | Healthcare | 1.32% | $2.8M | — | — |
| 28 | CELC | Celcuity Inc. | Healthcare | 1.30% | $2.7M | $2.77B | — |
| 29 | NUVB | Nuvation Bio Inc. | Healthcare | 1.02% | $2.2M | $1.56B | — |
| 30 | KURA | Kura Oncology, Inc. | Healthcare | 0.99% | $2.1M | $807.8M | — |
| 31 | GILD | Gilead Sciences, Inc. | Healthcare | 0.96% | $2.0M | $193.67B | — |
| 32 | NTRA | Natera, Inc. | Healthcare | 0.94% | $2.0M | $56.71B | — |
| 33 | URGN | UroGen Pharma Ltd. | Healthcare | 0.91% | $1.9M | $1.69B | — |
| 34 | NK | NantKwest Inc | Healthcare | 0.91% | $1.9M | — | — |
| 35 | RCUS | Arcus Biosciences, Inc. | Healthcare | 0.84% | $1.8M | $2.82B | — |
| 36 | ORIC | ORIC Pharmaceuticals, Inc. | Healthcare | 0.79% | $1.7M | $1.28B | — |
| 37 | GH | Guardant Health, Inc. | Healthcare | 0.72% | $1.5M | $21.28B | — |
| 38 | INBX | Inhibrx, Inc. | Healthcare | 0.71% | $1.5M | $1.32B | — |
| 39 | BCTG | BCTG Acquisition Corp | Financial Services | 0.71% | $1.5M | — | — |
| 40 | IMCR | Immunocore Holdings plc | Healthcare | 0.70% | $1.5M | $1.51B | — |
| 41 | CRVS | Corvus Pharmaceuticals, Inc. | Healthcare | 0.69% | $1.5M | $800.8M | — |
| 42 | REPL | Replimune Group, Inc. | Healthcare | 0.61% | $1.3M | $1.02B | — |
| 43 | ANL | Adlai Nortye Ltd. ADR | Healthcare | 0.57% | $1.2M | $710.3M | — |
| 44 | VSTM | Verastem, Inc. | Healthcare | 0.56% | $1.2M | $783.4M | — |
| 45 | IMTX | Immatics N.V. | Healthcare | 0.56% | $1.2M | $1.02B | — |
| 46 | FXFXX | First American Funds Inc. - Treasury Obligations Fund | Other | 0.49% | $1.0M | — | — |
| 47 | JANX | Janux Therapeutics, Inc. | Healthcare | 0.46% | $969,631.97 | $1.01B | — |
| 48 | ANAB | AnaptysBio, Inc. | Healthcare | 0.45% | $948,970.10 | $1.39B | — |
| 49 | CGEM | Cullinan Oncology, Inc. | Healthcare | 0.43% | $916,923.12 | $794.7M | — |
| 50 | CADL | Candel Therapeutics, Inc. | Healthcare | 0.37% | $784,729.33 | $626.7M | — |
| 51 | BCAX | Bicara Therapeutics Inc. | Healthcare | 0.35% | $733,074.66 | $1.11B | — |
| 52 | AVBP | ArriVent BioPharma, Inc. | Healthcare | 0.34% | $726,960.44 | $821.5M | — |
| 53 | MRNA | Moderna, Inc. | Healthcare | 0.30% | $628,921.98 | $87.04B | — |
| 54 | OLMA | Olema Pharmaceuticals, Inc. | Healthcare | 0.30% | $627,867.80 | $575.7M | — |
| 55 | CTMX | CytomX Therapeutics, Inc. | Healthcare | 0.29% | $619,012.71 | $496.8M | — |
| 56 | TYRA_old | TYRA | Healthcare | 0.29% | $610,790.13 | — | — |
| 57 | ARVN | Arvinas, Inc. | Healthcare | 0.22% | $462,783.69 | $449.7M | 26.8 |
| 58 | AUTL | Autolus Therapeutics plc | Healthcare | 0.21% | $445,284.35 | $425.9M | — |
Weights as a percentage of net assets. Value held = weight × net assets ($210.8M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
CANC sector breakdown
| Sector | Weight | Holdings | Largest |
|---|---|---|---|
| Healthcare | 98.3% | 56 | RVMD, MRK, LLY |
| Financial Services | 0.7% | 1 | BCTG |
| Other | 0.5% | 1 | FXFXX |
Sum of the weights of the holdings in each sector.
CANC top industries
CANC overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| DIA | SPDR Dow Jones Industrial Average ETF | 5.6% | 3 of 30 | 0.16% |
| SPY | SPDR S&P 500 ETF | 4.5% | 8 of 502 | 0.09% |
| VTI | Vanguard Total Stock Market ETF | 4.5% | 45 of 2,941 | 0.03% |
| QQQ | Invesco QQQ ETF | 2.2% | 3 of 101 | 0.17% |
| IWM | iShares Russell 2000 ETF | 1.6% | 27 of 1,962 | 0.19% |
| VXUS | Vanguard Total International Stock ETF | 1.1% | 3 of 8,035 | 0.05% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the CANC portfolio
Tema Oncology ETF holds 58 positions. The ten largest make up 42.6% of the fund and the top 50 97.2%, so it behaves like a portfolio of about 34 equally weighted stocks. The biggest positions are Revolution Medicines, Inc. (5.62%), Merck & Co., Inc. (5.30%), Eli Lilly and Company (4.96%), Cogent Biosciences, Inc. (4.81%), Novartis AG (3.85%).
By sector, Healthcare is 98.3%, Financial Services is 0.7%, Other is 0.5%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 24, 2026; positions change as the fund rebalances.
Related: CANC chart, CANC performance, CANC dividends, CANC overview.
CANC holdings FAQ
How many holdings does CANC have?
CANC holds 58 positions as of October 24, 2026.
What are the top 10 holdings of CANC?
The ten largest holdings are Revolution Medicines, Inc. (5.62%), Merck & Co., Inc. (5.30%), Eli Lilly and Company (4.96%), Cogent Biosciences, Inc. (4.81%), Novartis AG (3.85%), AbbVie Inc. (3.76%), Genmab A/S (3.70%), Halozyme Therapeutics, Inc. (3.63%), BeiGene, Ltd. (3.59%), Exelixis, Inc. (3.37%). Together they are 42.6% of the fund.
What percentage of CANC is Revolution Medicines, Inc.?
Revolution Medicines, Inc. is the largest holding at 5.62% of net assets, about $11.9M of the fund's $210.8M.
Which sector is the largest in CANC?
Healthcare is the largest sector at 98.3%, followed by Financial Services (0.7%) and Other (0.5%), based on the sectors of the individual holdings.
How concentrated is CANC?
The top 10 holdings are 42.6% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) CANC behaves like a portfolio of about 34 equally weighted stocks.